Senior Director, Tilrekimig Launch Operations

Global Commercial Strategy (GCS): Senior Director, Tilrekimig Launch Operations

Why Patients Need You

Everything we do, every day, is driven by an unwavering commitment to the patients, healthcare providers, and customers who depend on us. In Global Commercial Strategy (GCS), we translate science of R&D into value for patients and Pfizer — from early development through launch, growth, and LOE lifecycle. GCS serves as the strategic engine and commercial voice across the asset lifecycle — shaping asset positioning and evidence generation, leading global launches, and driving sustained access and brand performance through market and payer insights, broad access, & commercial rigor. We take pride in shaping how innovative medicines reach the people who need them most, and ensuring they are accessible, understood, and valued across every market. Our success is anchored in the following Pfizer Blueprint values: Science, Technology, Transformation and Colleagues. Whether you are defining strategy, managing brands at different lifecycle, or building the capabilities that power our commercial engine, your work directly shapes patient outcomes and the long-term success of Pfizer's portfolio.

Role Summary:

The Senior Director, Tilrekimig is a senior individual contributor role within the Inflammation & Immunology (I&I) / Rare Disease business, part of the Global Commercial Strategy organization, reporting to the Global Commercial Lead (GCL), CIB/TIL. This role has no direct reports and will lead through senior matrix leadership. As the Launch Operations Lead for tilrekimig, the role is responsible for enabling flawless operational execution of the global launch plan — driving cross-functional integration, timelines, governance, and launch readiness across all three indications. The mandate spans both strategic and operational deliverables for a blockbuster launch of high complexity, but is more operational than the Global Launch Lead role, ensuring the GCL and leadership teams have the structure, tools, insights, and processes to accelerate tilrekimig’s path to launch.

The broader I&I and Rare Disease portfolio represents significant strategic value to realizing Pfizer's vision to achieve leadership via breakthroughs in prioritized diseases and biological axes, with the goal of generating highly differentiated, multi-indication mega-blockbusters. Today, the portfolio delivers more than $10B globally, with 22 ongoing clinical studies underway to significantly expand the product portfolio over the next several years. This role will contribute to that ambition by helping shape the commercial strategy and launch foundation for a high-priority I&I pipeline asset with potential to address significant unmet need across Type 2 inflammatory diseases.

Tilrekimig (PF-07275315) is an investigational trispecific antibody with potential to be a first-in-class, once-monthly treatment option targeting interleukin-4 (IL-4), interleukin-13 (IL-13), and thymic stromal lymphopoietin (TSLP) for multiple chronic Type 2 inflammatory conditions, including atopic dermatitis, asthma, and chronic obstructive pulmonary disease (COPD). Following positive Phase 2 results in moderate to severe atopic dermatitis and ongoing development across additional Type 2 inflammatory diseases, this colleague will help translate scientific and clinical potential into a launch-ready operational foundation, integrated cross-functional execution, and a clear, well-governed path to launch for patients, healthcare providers, payers, and markets.

The Senior Director will partner closely with the GCL (CIB/TIL), R&D, Medical Affairs, Global Access Strategy & Pricing (GASP), Business Analytics & Insights, Competitive Intelligence, Regulatory, Legal, Compliance, CMO, and US and International Commercial teams to drive cross-functional integration, manage launch timelines and governance, anticipate operational risks, and ensure launch readiness is grounded in patient need, scientific differentiation, access considerations, competitive dynamics, and enterprise value.

Responsibilities:

Global Launch Strategy and Enterprise Launch Program Management (DLPP):

· Deliver the Global Integrated Launch Strategy, including evidence positioning, indication sequencing, indication-specific value propositions, and portfolio integration.

· Lead end-to-end launch operations, including timelines, critical path management, risk mitigation plans, and scenario-planning frameworks.

· Maintain the cross-indication Launch Roadmap (DLPP) covering asset, evidence, regulatory, supply, medical, commercial, and regional readiness.

·  Integrate atopic dermatitis learnings and support new Respiratory capabilities (asthma and COPD) across the organization.

· Champio